A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy
Johnson & Johnson · Vivli · 2019
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Vivli · Vivli · dataset · 2019
Abstract
The purpose of this study is to evaluate the impact on survival and quality of life of maintaining hemoglobin in the range of 12 to 14 g/dL using epoetin alfa or placebo in patients starting chemotherapy for metastatic breast cancer for the first time.
Open the resolved locator · 10.25934/00004635
Metadata licence: OpenAlex metadata (CC0)